Checkpoint Trends Ltd
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
- Market Cap ₹ 22.5 Cr.
- Current Price ₹ 41.2
- High / Low ₹ 42.0 / 6.08
- Stock P/E 751
- Book Value ₹ 1.02
- Dividend Yield 0.00 %
- ROCE 9.17 %
- ROE 5.50 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 40.2 times its book value
- The company has delivered a poor sales growth of -12.8% over past five years.
- Company has a low return on equity of -1.24% over last 3 years.
- Company has high debtors of 212 days.
- Working capital days have increased from 220 days to 387 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.20 | 0.31 | 2.30 | 0.59 | 0.99 | 0.49 | 2.01 | 1.16 | 1.13 | 0.50 | |
0.06 | 0.07 | 0.21 | 0.28 | 2.33 | 0.77 | 0.97 | 0.48 | 2.03 | 1.24 | 1.10 | 0.44 | |
Operating Profit | -0.06 | -0.07 | -0.01 | 0.03 | -0.03 | -0.18 | 0.02 | 0.01 | -0.02 | -0.08 | 0.03 | 0.06 |
OPM % | -5.00% | 9.68% | -1.30% | -30.51% | 2.02% | 2.04% | -1.00% | -6.90% | 2.65% | 12.00% | ||
0.00 | -3.00 | 0.00 | 0.00 | -0.13 | 0.17 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Profit before tax | -0.06 | -3.07 | -0.01 | 0.03 | -0.16 | -0.01 | 0.05 | 0.01 | -0.02 | -0.08 | 0.02 | 0.05 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.00% | 0.00% | 50.00% | 0.00% | -50.00% | 40.00% |
-0.06 | -3.07 | -0.01 | 0.03 | -0.16 | -0.01 | 0.03 | 0.01 | -0.04 | -0.08 | 0.03 | 0.03 | |
EPS in Rs | -0.11 | -5.61 | -0.02 | 0.05 | -0.29 | -0.02 | 0.05 | 0.02 | -0.07 | -0.15 | 0.05 | 0.05 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -13% |
3 Years: | -37% |
TTM: | -56% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 25% |
3 Years: | 40% |
TTM: | 0% |
Stock Price CAGR | |
---|---|
10 Years: | 32% |
5 Years: | 82% |
3 Years: | 112% |
1 Year: | 339% |
Return on Equity | |
---|---|
10 Years: | -1% |
5 Years: | -2% |
3 Years: | -1% |
Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 |
Reserves | -2.00 | -5.08 | -5.08 | -5.05 | -4.87 | -4.89 | -4.85 | -4.85 | -4.88 | -4.96 | -4.94 | -4.91 |
0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 0.00 | 0.00 | |
0.08 | 0.07 | 0.06 | 0.11 | 0.21 | 0.12 | 0.13 | 0.29 | 0.26 | 0.00 | 0.40 | 0.09 | |
Total Liabilities | 3.78 | 0.46 | 0.45 | 0.53 | 0.81 | 0.70 | 0.75 | 0.91 | 0.85 | 0.66 | 0.93 | 0.65 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.06 | 0.07 | 0.00 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
3.78 | 0.46 | 0.45 | 0.53 | 0.81 | 0.68 | 0.73 | 0.90 | 0.84 | 0.60 | 0.86 | 0.65 | |
Total Assets | 3.78 | 0.46 | 0.45 | 0.53 | 0.81 | 0.70 | 0.75 | 0.91 | 0.85 | 0.66 | 0.93 | 0.65 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -0.08 | -0.01 | 0.04 | 0.18 | -0.03 | 0.12 | 0.52 | -0.50 | 0.01 | -0.02 | 0.19 | |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.18 | |
0.06 | -0.23 | -0.02 | 0.02 | 0.00 | -0.17 | -0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | 0.01 | -0.31 | -0.03 | 0.06 | 0.18 | -0.20 | -0.14 | 0.52 | -0.50 | 0.01 | -0.02 | 0.01 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 36.50 | 23.55 | 53.96 | 179.41 | 106.92 | 163.88 | 121.67 | 135.30 | 229.34 | 211.70 | ||
Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 36.50 | 23.55 | 53.96 | 179.41 | 106.92 | 163.88 | 121.67 | 135.30 | 229.34 | 211.70 | ||
Working Capital Days | 18.25 | -35.32 | 36.50 | 259.83 | 221.21 | 59.59 | 98.06 | 129.01 | 145.35 | 386.90 | ||
ROCE % | -1.62% | -3.42% | -2.56% | 7.41% | 25.49% | -30.51% | 3.33% | 1.61% | -3.31% | -12.80% | 3.36% | 9.17% |
Documents
Announcements
-
Board Meeting Intimation for To Approve The Unaudited Standalone Financial Results Of The Company For The Quarter Ended On June 30, 2025
29 Jul - Board meeting on Aug 6 to approve Q1 June 30, 2025 unaudited financial results.
-
Special Window For Re-Lodgement Of Transfer Requests For Physical Shares
29 Jul - Special window from July 7, 2025 to Jan 6, 2026 for re-lodging rejected physical share transfers.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
17 Jul - Confirmation certificate filed under SEBI regulation for quarter ended June 30, 2025.
-
Closure of Trading Window
27 Jun - Trading window closed from July 1, 2025, till 48 hours after June quarter results declaration.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Jun - Newspaper publication for audited financial result for the quarter and year ended March 31, 2025
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
CTL (Formerly Rubra Medicaments Ltd) was engaged in the manufacture and sale of pharmaceutical formulations based in Hyderabad. The company is currently in the business of trading and providing different kinds of consulting services in India to all categories of clients.